- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07603765
Minimally Invasive Hemodynamic Monitoring in Cardiac Ablation
Prospective Clinical Study of Minimally Invasive Hemodynamic Monitoring Outcomes in Cardiac Ablation Procedures
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Cardiac ablation procedures performed in electrophysiology laboratories are increasingly complex and frequently conducted under non-operating room anesthesia (NORA). These procedures carry a risk of hemodynamic instability due to arrhythmia induction, procedural manipulation, and potential complications such as cardiac tamponade, thromboembolism, or fluid overload. Continuous and accurate hemodynamic monitoring is therefore essential for optimal patient management. However, data on the use of minimally invasive hemodynamic monitoring techniques in this setting remain limited.
This prospective observational clinical study aims to evaluate the clinical utility of Pressure Recording Analytical Method (PRAM)-based minimally invasive hemodynamic monitoring in patients undergoing cardiac ablation procedures. The study will be conducted in the cardiac catheterization laboratory of Istanbul University-Cerrahpaşa Cardiology Institute and will include 27 adult patients scheduled for catheter ablation. Written informed consent will be obtained from all participants, and the study will adhere to the principles of the Declaration of Helsinki.
All patients will undergo standard monitoring, including electrocardiography, heart rate, pulse oximetry, and invasive arterial blood pressure measurement via radial or femoral arterial access. In addition, continuous beat-to-beat hemodynamic data will be obtained using the MostCare® system, which applies the PRAM algorithm for real-time waveform analysis.
Primary hemodynamic parameters include heart rate, systolic, diastolic, and mean arterial pressures. Advanced parameters such as stroke volume, cardiac output, cardiac index, systemic vascular resistance, stroke volume variation, pulse pressure variation, dP/dt max, and cardiac cycle efficiency will also be recorded. Measurements will be collected at three predefined time points: before ablation (T0), during ablation (T1), and after ablation (T2).
The primary objective is to assess time-dependent changes in hemodynamic parameters and evaluate the contribution of PRAM-based monitoring to intra-procedural patient management. Secondary aims include generating evidence to support anesthesiologists' clinical decision-making and contributing to the development of future guidelines for high-risk NORA settings.
Statistical analysis will be performed using repeated measures methods, with a significance level set at p<0.05.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Istanbul, Turquie (Türkiye)
- Istanbul University-Cerrahpasa, Institute of Cardiology
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Age ≥18 years
- Patients scheduled for cardiac catheter ablation in the electrophysiology laboratory
- Indication for ablation confirmed by a cardiologist
- Ability to provide written informed consent
- Planned invasive arterial blood pressure monitoring during the procedure
Exclusion Criteria:
- Refusal or inability to provide informed consent
- Failure to identify arrhythmogenic focus leading to cancellation of ablation procedure
- Severe hemodynamic instability prior to procedure
- Contraindication to invasive arterial catheterization
- Incomplete hemodynamic data acquisition
- Pregnancy
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Cardiac Output measured by PRAM during catheter ablation
Délai: Intra-procedural (T0: before ablation, T1: during ablation, T2: after ablation)
|
Cardiac output (L/min) measured using the PRAM-based monitoring system during catheter ablation procedures under non-operating room anesthesia.
|
Intra-procedural (T0: before ablation, T1: during ablation, T2: after ablation)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Stroke Volume During Catheter Ablation
Délai: Intra-procedural (T0: before ablation, T1: during ablation, T2: after ablation)
|
Stroke volume (mL/beat) measured using PRAM-based hemodynamic monitoring during the procedure.
|
Intra-procedural (T0: before ablation, T1: during ablation, T2: after ablation)
|
|
Change in Mean Arterial Pressure During Catheter Ablation
Délai: Intra-procedural (T0: before ablation, T1: during ablation, T2: after ablation)
|
Mean arterial pressure (mmHg) measured invasively and analyzed during the procedure.
|
Intra-procedural (T0: before ablation, T1: during ablation, T2: after ablation)
|
|
Change in Systemic Vascular Resistance During Catheter Ablation
Délai: Intra-procedural (T0: before ablation, T1: during ablation, T2: after ablation)
|
Systemic vascular resistance (dyn·s/cm⁵) measured using PRAM-based monitoring during catheter ablation.
|
Intra-procedural (T0: before ablation, T1: during ablation, T2: after ablation)
|
|
Change in dP/dt max During Catheter Ablation
Délai: Intra-procedural (T0: before ablation, T1: during ablation, T2: after ablation)
|
Maximum arterial pressure rise over time (dP/dt max, mmHg/s) measured using PRAM-based analysis.
|
Intra-procedural (T0: before ablation, T1: during ablation, T2: after ablation)
|
|
Change in Cardiac Cycle Efficiency During Catheter Ablation
Délai: Intra-procedural (T0: before ablation, T1: during ablation, T2: after ablation)
|
Cardiac cycle efficiency (%) assessed using the PRAM-based monitoring system during catheter ablation.
|
Intra-procedural (T0: before ablation, T1: during ablation, T2: after ablation)
|
|
Change in Arterial Elastance
Délai: Intra-procedural (T0: before ablation, T1: during ablation, T2: after ablation)
|
Change in arterial elastance derived from PRAM across predefined procedural periods: before, during, and after catheter ablation.
Arterial elastance will be expressed as mmHg/mL.
|
Intra-procedural (T0: before ablation, T1: during ablation, T2: after ablation)
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chaise d'étude: Kerem Erkalp, Istanbul University-Cerrahpasa, Institute of Cardiology
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- 018
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .